
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals is supported by a 3Q 2026 beat on both revenue and EPS, with sales of $290.8M and non-GAAP EPS of $2.70, driven by stronger Generics performance and lower SG&A and R&D spending. Although Cortrophin sales of $138.66M missed expectations and FY 2026 guidance was cut to $480M-$500M, management framed the shortfall as a conversion bottleneck rather than weaker demand, citing doubled new gout cases QoQ and a 67% QoQ increase in gout prescribers. The proposed Egetis Therapeutics acquisition, plus stronger Iluvien sales of $22.3M and a rare-disease strategy that deepens ANI’s portfolio, supports the view that the company can compound growth while shifting toward higher-value specialty assets.
Bears say
ANI Pharmaceuticals is facing a fragile outlook because its most important growth drivers remain exposed to unforeseen clinical, regulatory, manufacturing, or commercial setbacks or delays, particularly for Purified Cortrophin Gel and Iluvien. The company also has execution risk from continued challenges with the Alimera integration and uncertainty around its ability to complete attractive future deals, which could slow the expected contribution from its Rare Disease and Brands businesses. Meanwhile, worsening pricing and competitive pressures in the generics industry threaten the Generics and Other segment, increasing the risk that overall revenue and margin performance will remain under pressure.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About ANI Pharma (ANIP) Forecast
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares